Why the study?
Does argatroban reduce thrombin generation compared to heparin in sham ECMO circuits?
Does argatroban reduce thrombin generation compared to heparin in sham ECMO circuits?
Argatroban may be a more efficacious alternative to heparin for anticoagulation in ECMO circuits, as it decreased thrombin generation in a sham circuit model.
Answers are grounded in this paper and cite their sources.
Argatroban may warrant evaluation versus heparin for ECMO anticoagulation; hypothesis-generating in animal models and requires clinical validation.
We investigated the anticoagulant effects of argatroban, a direct thrombin inhibitor, versus heparin in extracorporeal membrane oxygenation (ECMO) circuits. Three sham circuits were prepared according to our hospital's standard practice and run for six hours simultaneously. Two circuits were anticoagulated with argatroban (one with heparin in the wet prime and one without). One circuit had heparin in the initial prime and was then anticoagulated with heparin. We measured thrombin generation (prothrombin fragment 1+2, D-dimer and thrombin-antithrombin complexes), activated clotting times (ACTs) and partial thromboplastin times (aPTTs), and monitored thrombus formation using thromboelastography. ACTs were >1000 s in each circuit throughout assessment. No clot initiation was detected by thromboelastography. Thrombin generation was decreased in circuits anticoagulated with argatroban versus heparin, despite aPTTs being less prolonged. These results suggest that argatroban may be more efficacious than heparin for anticoagulation in ECMO. Additional studies are warranted to further evaluate argatroban in this setting.
No takes yet. Share an insight, caveat, or question.
Young et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: